TOWARDS REALIST-INFORMED RIPPLE EFFECTS MAPPING (RREM): POSITIONING THE APPROACH


Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific click here T cell engager (BiTE) therapy to manage myeloid malignancies has proven more challenging than for B-cell malignancies.This is attributed to a shortage of leukemia-specific cell-surface antigens that distinguish healthy from malignant myelo

read more